Neumora Therapeutics (NMRA) News Today → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free NMRA Stock Alerts $9.51 +0.34 (+3.71%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 22, 2024 | finance.yahoo.comThis Neumora Therapeutics Insider Increased Their Holding In The Last YearMay 22, 2024 | americanbankingnews.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMay 14, 2024 | globenewswire.comNeumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar DepressionMay 10, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Trading Down 7.5%Neumora Therapeutics (NASDAQ:NMRA) Shares Down 7.5%May 10, 2024 | marketbeat.comWilliam Blair Brokers Lower Earnings Estimates for Neumora Therapeutics, Inc. (NASDAQ:NMRA)Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Stock analysts at William Blair lowered their Q3 2024 EPS estimates for Neumora Therapeutics in a research report issued on Tuesday, May 7th. William Blair analyst M. Minter now expects that the company will earn ($0.37) per share for the qMay 8, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Posts Earnings Results, Hits ExpectationsNeumora Therapeutics (NASDAQ:NMRA - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.34) EPS for the quarter, hitting the consensus estimate of ($0.34).May 8, 2024 | finanznachrichten.deNeumora Therapeutics, Inc.: Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 7, 2024 | investorplace.comNMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024May 7, 2024 | globenewswire.comNeumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 6, 2024 | finance.yahoo.comNeumora Therapeutics to Participate in Upcoming Conferences in MayMay 2, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Sees Strong Trading VolumeNeumora Therapeutics (NASDAQ:NMRA) Sees Large Volume IncreaseApril 29, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Stock Price Up 6.2%Neumora Therapeutics (NASDAQ:NMRA) Trading 6.2% HigherApril 27, 2024 | msn.comParkinson’s UK invests £2.1 million in Neumora Therapeutics for preclinical testing of new Parkinson’s drugApril 27, 2024 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have been given an average rating of "Moderate Buy" by the seven research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and six have issued a buyApril 25, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Sets New 52-Week Low at $8.98Neumora Therapeutics (NASDAQ:NMRA) Hits New 1-Year Low at $8.98April 24, 2024 | finance.yahoo.comWe're Hopeful That Neumora Therapeutics (NASDAQ:NMRA) Will Use Its Cash WiselyApril 19, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Trading Down 4.6%Neumora Therapeutics (NASDAQ:NMRA) Trading Down 4.6%April 18, 2024 | finance.yahoo.comBiotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study SuccessApril 17, 2024 | msn.comNeumora Therapeutics (NMRA) Price Target Increased by 6.99% to 25.76April 17, 2024 | nasdaq.comNeumora Therapeutics Becomes Oversold (NMRA)April 16, 2024 | finanznachrichten.deNeumora Therapeutics, Inc.: Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 StudyApril 15, 2024 | bizjournals.comFDA pauses Watertown biotech’s schizophrenia trialApril 15, 2024 | finance.yahoo.comNeumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia DrugApril 15, 2024 | finance.yahoo.comWhy Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday?April 15, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Shares Gap Down to $13.56Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Down to $13.56April 15, 2024 | marketwatch.comNeumora Shares Slide Premarket as FDA Puts Early Study of Schizophrenia Drug on HoldApril 15, 2024 | markets.businessinsider.comFDA Places Clinical Hold On Neumora's Phase 1 Study Of NMRA-266; Stock Tanks In Pre-MarketApril 15, 2024 | investorplace.comWhy Is Neumora Therapeutics (NMRA) Stock Down 25% Today?April 15, 2024 | globenewswire.comNeumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 StudyApril 12, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Given Outperform Rating at William BlairWilliam Blair reiterated an "outperform" rating on shares of Neumora Therapeutics in a research report on Friday.April 11, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Trading Down 4.4%Neumora Therapeutics (NASDAQ:NMRA) Shares Down 4.4%April 2, 2024 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have aApril 1, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Stock Price Up 4.3%Neumora Therapeutics (NASDAQ:NMRA) Trading 4.3% HigherMarch 28, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Receives "Outperform" Rating from Royal Bank of CanadaRoyal Bank of Canada reiterated an "outperform" rating and issued a $31.00 target price on shares of Neumora Therapeutics in a report on Thursday.March 25, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Shares Gap Down to $13.21Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Down to $13.21March 22, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Trading Down 6.9%Neumora Therapeutics (NASDAQ:NMRA) Stock Price Down 6.9%March 18, 2024 | marketbeat.comJPMorgan Chase & Co. Increases Neumora Therapeutics (NASDAQ:NMRA) Price Target to $22.00JPMorgan Chase & Co. upped their price target on shares of Neumora Therapeutics from $20.00 to $22.00 and gave the stock an "overweight" rating in a report on Monday.March 16, 2024 | finance.yahoo.comNMRA Apr 2024 17.500 putMarch 14, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Trading 3.6% Higher Neumora Therapeutics (NASDAQ:NMRA) Stock Price Up 3.6%March 14, 2024 | finance.yahoo.cominstitutional investors of Neumora Therapeutics, Inc. (NASDAQ:NMRA) must be disappointed after last week's 20% dropMarch 13, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Shares Gap Down to $17.35Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Down to $17.35March 13, 2024 | globenewswire.comNeumora Therapeutics to Participate at Stifel 2024 Virtual CNS DaysMarch 8, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPSNeumora Therapeutics (NASDAQ:NMRA - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.71) EPS for the quarter, topping analysts' consensus estimates of ($0.76) by $0.05.March 8, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Sets New 12-Month High on Earnings BeatNeumora Therapeutics (NASDAQ:NMRA) Reaches New 52-Week High Following Better-Than-Expected EarningsMarch 8, 2024 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Recommendation of "Moderate Buy" from AnalystsNeumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) has received an average recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and six have issued a buy raMarch 7, 2024 | investorplace.comNMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023March 7, 2024 | finanznachrichten.deNeumora Therapeutics, Inc.: Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 7, 2024 | globenewswire.comNeumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 28, 2024 | marketbeat.comFmr LLC Acquires New Shares in Neumora Therapeutics, Inc. (NASDAQ:NMRA)Fmr LLC purchased a new stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 5,624,353 shares of the company's stock, valued at apFebruary 15, 2024 | finance.yahoo.comNMRA Feb 2024 12.500 call Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Log Into Marc's $5,000 System Today (Ad)New Panic Could Sweep America Mark these words in 2024. Everyone's going to cash… Wall Street legend says: "A little-known vehicle outside of banks could double… triple… or even quadruple your life savings if you know where to find it right now." We urge you to move your cash into this vehicle in 2024. More here. NMRA Media Mentions By Week NMRA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NMRA News Sentiment▼1.240.87▲Average Medical News Sentiment NMRA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NMRA Articles This Week▼42▲NMRA Articles Average Week Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Vir Biotechnology News Today Ginkgo Bioworks News Today Tarsus Pharmaceuticals News Today BioCryst Pharmaceuticals News Today 4D Molecular Therapeutics News Today Sana Biotechnology News Today Autolus Therapeutics News Today Beam Therapeutics News Today Cullinan Therapeutics News Today CG Oncology News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NMRA) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersRevealed: The Unknown Biotech Powering AI in HealthcareBehind the MarketsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaWARNING about the death of the U.S. dollar…Colonial MetalsDigitizing the $11T commodities sector with one tiny stockResource Stock DigestTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsElon’s New Device is About to Shock the WorldInvestorPlaceHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.